Melanotan II Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What Melanotan II Does & How It Works

What It Does , Functional Outcomes

The Melanotan II peptide is a non-selective melanocortin receptor agonist, which means it activates multiple receptor subtypes at once and produces several distinct physiological effects simultaneously. Here is what that looks like at the functional level:

• Stimulates skin darkening (tanning) by activating pigment-producing cells without requiring UV radiation
• Initiates erections through central nervous system pathways, independent of peripheral sexual stimulation
• Increases sexual desire and arousal in both males and females
• Suppresses appetite through hypothalamic receptor activation, though tolerance develops within approximately 8-12 days of continuous use
• Increases thermogenesis - the body's heat production and fat-burning activity
• Reduces markers of inflammation through immune cell receptor activation
• Produces neuroprotective effects in animal models of nerve injury and neurodegeneration

How It Works , Mechanism of Action

Melanotan II is a non-selective agonist of four of the five known melanocortin receptor subtypes: MC1R, MC3R, MC4R, and MC5R. It does not activate MC2R (the receptor for the stress hormone ACTH). All four activated receptor types are G protein-coupled receptors - meaning they sit on cell surfaces and relay signals into the cell by triggering a cascade of molecular events when MT2 binds to them. The breadth of this receptor activation is what makes Melanotan II both pharmacologically fascinating and clinically difficult: every dose activates all four pathways simultaneously.

MC1R Activation - Skin Pigmentation (Evidence: Human and in vitro)

When MT2 binds MC1R on melanocytes - the pigment-producing cells in skin - it elevates a signaling molecule called cyclic AMP inside the cell. This triggers a chain reaction involving Protein Kinase A and a transcription factor called CREB, ultimately driving expression of MITF, the master regulator of melanocyte biology. MITF then ramps up production of tyrosinase, the enzyme that controls melanin synthesis. The result is increased eumelanin (the dark pigment) in skin without any UV exposure. Effects become visible within 2-5 days and persist for months after cessation due to melanin loading in melanocytes.

MC4R Activation - Sexual Function (Evidence: Human clinical trial)

MC4R activation in the paraventricular nucleus of the hypothalamus and spinal cord initiates pro-erectile signaling through neuronal nitric oxide release in erectile tissue. This is mechanistically distinct from how PDE5 inhibitors like sildenafil work - those compounds act at the periphery to prevent nitric oxide breakdown once vascular signaling is already happening. MT2 acts upstream, in the brain, to initiate the arousal cascade itself. In the landmark Wessells et al. (1998) trial, erections occurred in 85% of men with erectile dysfunction in the complete absence of sexual stimulation - a finding that can only be explained by central nervous system initiation.

MC3R/MC4R Activation - Energy Homeostasis and Appetite (Evidence: Animal models)

MC3R and MC4R activation in the hypothalamus suppresses appetite through central signaling pathways. The same receptor activation also engages the sympathetic nervous system, increases noradrenaline signaling to brown adipose tissue, and upregulates uncoupling protein-1 (UCP-1), the protein responsible for generating heat rather than ATP from fat. Dhurandhar et al. (2013) demonstrated in diet-induced obese rats that body mass reduction was maintained even after the appetite-suppressing effect wore off, suggesting that thermogenic mechanisms operate independently of appetite and are more resistant to the tolerance that develops for appetite suppression around 8-12 days of continuous use.

MC1R Activation - Anti-Inflammatory Effects (Evidence: In vitro)

MC1R is expressed on immune cells as well as skin cells. When activated on immune cells, it suppresses key inflammatory signals: it reduces NF-kappaB activity, decreases pro-inflammatory cytokines including IL-1, IL-6, IL-8, and TNF-alpha, and elevates the anti-inflammatory cytokine IL-10. It also reduces COX-2 expression and the prostaglandin PGE2 that COX-2 produces. These are well-characterized pathways in inflammatory biology, though the clinical significance of MT2's anti-inflammatory effects in humans has not been directly studied.

Melanotan II Molecular Profile

Structure reference: View on PubChem CID 92432 - Publishing team: retrieve 2D structure image from this link.

The structural engineering of Melanotan II is worth understanding because it explains almost everything about why this compound behaves so differently from the natural hormone it mimics. Native alpha-MSH is a linear 13-amino acid peptide with a half-life measured in minutes - enzymes in blood and tissue dismantle it almost immediately. MT2 is a 7-residue cyclic structure: a ring formed by a lactam bridge between aspartic acid and lysine, with a D-amino acid substitution and norleucine replacing oxidation-prone methionine. Each modification closes off a route by which peptidases would normally degrade the molecule. The result is a compound with a half-life of approximately 33 hours and roughly 1,000-fold greater potency than the natural hormone it is derived from. The cyclic structure also enables passage through the blood-brain barrier - a property absent in linear alpha-MSH analogs - which is what makes the central effects on sexual function and appetite pharmacologically possible.

Melanotan II Uses & Benefits

Tanning and Skin Pigmentation

The original and most established application for Melanotan II is its ability to produce skin darkening without UV exposure. Users seek this effect for cosmetic tanning purposes - getting a darker skin tone without sun exposure or tanning beds. MC1R activation drives eumelanin synthesis in melanocytes throughout the skin, producing pigmentation that resembles a natural tan. Effects become visible within 2-5 days and accumulate with ongoing use, with pigmentation persisting for weeks to months after cessation. The same mechanism is the basis for the FDA-approved compound afamelanotide (Scenesse), which uses a related but linear analog of alpha-MSH to treat erythropoietic protoporphyria. (Evidence: Human - pigmentation documented in clinical research - Dorr et al., 1996, Journal of Investigative Dermatology)

Erectile Dysfunction and Male Sexual Function

Melanotan II has the most robust human clinical data for erectile dysfunction of any indication it has been studied for. The Wessells et al. (1998) double-blind, placebo-controlled crossover trial documented erection initiation in 85% of men with psychogenic erectile dysfunction, occurring without any sexual stimulation, through a central nervous system mechanism. A follow-up trial (Wessells et al., 2000) extended findings to men with organic erectile dysfunction and documented subjective sexual desire increases in 68% of active treatment administrations versus 19% with placebo. The mechanism - central MC4R activation initiating arousal signaling at the brain level - is distinct from PDE5 inhibitors and theoretically relevant for cases where peripheral mechanisms are insufficient, such as neurogenic ED or cases involving absent sexual desire. (Evidence: Strong - human clinical trial - Wessells et al., 1998, Journal of Urology)

Female Sexual Dysfunction and Arousal

The same central MC4R pathway that drives arousal in males is present and functional in females, and Pfaus et al. (2004) documented selective facilitation of sexual solicitation behavior in female rats. This finding provided the mechanistic rationale for developing bremelanotide - MT2's successor compound - specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women, which it received FDA approval for in 2019. Human clinical data specifically for MT2 in female sexual function does not exist - the female-relevant findings are animal-model only. The successor compound represents the clinically validated path for this application. (Evidence: Preliminary - animal model - Pfaus et al., 2004, PNAS)

Appetite Suppression and Weight Management

MC3R and MC4R activation in the hypothalamus produces measurable appetite suppression and metabolic effects in animal models, including sustained body mass reduction and decreased intra-abdominal fat even after tolerance to the appetite-suppressing effect develops. The tolerance timeline - approximately 8-12 days for appetite effects - is the key practical limitation for any weight management application. No human clinical trial has evaluated Melanotan II for any metabolic or obesity indication, which is a significant gap given that all metabolic findings come from rodent models. (Evidence: Preliminary - animal model only - Dhurandhar et al., 2013, Applied Physiology, Nutrition, and Metabolism)

Neuroprotection and Nerve Regeneration

Animal models have documented that melanocortin agonism - including MT2-related compounds - protects against brain damage and cognitive decline in Alzheimer's transgenic mouse models, enhances peripheral nerve regeneration following crush injury, and provides partial protection against chemotherapy-induced toxic neuropathy. These findings align with MC1R-mediated suppression of neuroinflammation and effects on glial cell activity. No human neuroprotection data exists for Melanotan II, and this application has not been pursued in clinical development. (Evidence: Preliminary - animal models only)

Where This Guide Comes From

Melanotan II Results & Timelines

Skin Pigmentation and Tanning

• Days 2-5: Earliest visible skin darkening is typically reported within this window - confirming that MC1R-driven melanogenesis is producing eumelanin in skin
• Weeks 2-4: Progressive pigmentation development; darkening becomes more pronounced with continued administration
• Weeks 4-8: Most users reach their peak pigmentation response in this range; loading is typically considered complete
• After cessation: Pigmentation persists for weeks to months after stopping use; the cumulative nature of melanin loading in melanocytes means this is not a use-it-and-lose-it effect

Sexual Function

• Within 15-270 minutes post-injection: The range documented in published clinical research for onset of erectile response - this wide window reflects individual variation in pharmacodynamics; most effects are noted within 1-2 hours
• Duration: Published trials documented penile rigidity above 80% for 41-45 minutes in active treatment versus 2-3 minutes in placebo - a clinically meaningful difference
• Sexual desire: Increased subjective desire was reported in 68% of active treatment administrations in Wessells et al. (2000), though the onset timeline for desire effects is less precisely characterized than for erectile response

Appetite and Metabolic Effects

• Within hours: Rapid food intake suppression documented in animal research; human onset data is not available from clinical trials
• Days 1-8: Appetite-suppressing effects are most pronounced in this window based on animal model data
• Days 8-12: Tachyphylaxis (tolerance) to appetite effects develops within approximately this window in documented animal research; effects diminish
• Beyond 12 days: Metabolic effects - thermogenesis and fat mobilization - appear more resistant to tolerance than appetite suppression in animal models

How to Administer Melanotan II

Subcutaneous Injection (SubQ)

Subcutaneous injection is the only administration route used in published human clinical research for Melanotan II. All documented human data - the Wessells et al. trials for erectile function and the Dorr et al. pigmentation research - used subcutaneous administration. The extended half-life of approximately 33 hours means a single injection produces sustained receptor activation across multiple systems for over a day. Typical injection sites are the same as for other subcutaneous peptides - abdomen, upper thigh, or similar areas with accessible subcutaneous tissue.

Intramuscular Injection (IM)

Intramuscular administration has not been studied in published research for Melanotan II, and it is not a standard route in any documented clinical protocol. The subcutaneous route provides adequate bioavailability given the compound's structural resistance to degradation, so IM is not typically used or considered necessary.

Nasal / Intranasal

Nasal spray formulations have been explored and are widely sold via gray-market channels - primarily marketed for tanning and sexual function applications. This is an important safety consideration: gray-market nasal spray products are the most common form in which Melanotan II is sold outside of research contexts, and they carry the most significant quality and safety concerns given the complete absence of manufacturing oversight or purity verification. From a pharmacological standpoint, nasal absorption can bypass first-pass metabolism, but the specific bioavailability data for intranasal MT2 compared to subcutaneous MT2 is not well-characterized in peer-reviewed literature.

Oral

Oral administration of Melanotan II is not an effective route for achieving systemic effects. As a peptide, even one with enhanced enzymatic resistance from its cyclic structure and D-amino acid substitution, it is broken down in the gastrointestinal environment before reaching systemic circulation in meaningful concentrations. The protection that cyclization and D-Phe substitution provide against blood-borne and tissue peptidases is insufficient against the full gastrointestinal enzymatic environment. No published research documents oral administration as an effective route for any of MT2's studied effects.

Melanotan II Dosage & Cycle Length

Overall dosing reference: 0.025 mg/kg per subcutaneous injection - this is the dose used in the primary published human clinical trials (Wessells et al., 1998, 2000); real-world protocols in practice vary considerably from this reference point

How the goal shifts where you land:

• Pigmentation (tanning): Lower, less frequent doses are commonly associated with maintenance of established pigmentation once loading is achieved; higher or more frequent administration is associated with the initial loading phase to build up eumelanin
• Sexual function: The 0.025 mg/kg reference dose from clinical trials is the primary evidenced anchor; community-reported experience with sexual function applications tends to track closely to this range, with individual sensitivity varying meaningfully
• Metabolic and appetite effects: Animal model research used chronic administration protocols; the specific dose-response relationship in humans for metabolic applications has not been established in clinical trials

Frequency: Single administration prior to desired sexual function effect is the pattern used in published research; ongoing pigmentation protocols typically involve more frequent initial administration (loading phase) followed by reduced maintenance frequency

Cycle length: Pigmentation effects are cumulative and persistent - not cycle-dependent in the conventional sense; effects persist for weeks to months after cessation. Appetite-suppressing effects develop tachyphylaxis within 8-12 days of continuous use, which functionally limits any weight management application to short windows. Sexual function use is typically acute (single-dose administration before desired effect) rather than as a continuous cycle.

Tachyphylaxis: Tolerance to appetite-suppressing effects is documented in animal research within 8-12 days of continuous administration. Pigmentation effects do not show the same tolerance pattern - eumelanin accumulation in melanocytes is cumulative. Tolerance development for sexual function effects is less clearly characterized in published literature.

Melanotan II Vial Sizes, Costs & Quality

Common vial sizes: 10 mg vials are the most commonly available size for Melanotan II; 5 mg vials are also available from some suppliers

Typical cost range: $60-$120 per vial for U.S.-manufactured research-grade peptides at current market pricing - varies by supplier, vial size, and purity level

Storage - lyophilized (dry powder):

• Temperature: Long-term storage at -20 degrees C; the structural cyclization and D-amino acid substitution confer meaningful stability, but freezing is recommended for extended storage
• Shelf life: Typically 12-24 months when properly stored as lyophilized powder
• Light sensitivity: Protect from light; store in opaque containers

Storage - reconstituted (in solution):

• Temperature: Refrigerate at 2-8 degrees C after reconstitution
• Use window: Typically 28-30 days once reconstituted when stored under proper refrigeration

Normal appearance after reconstitution: Melanotan II dissolves into a clear, colorless solution when properly reconstituted. Any significant cloudiness, visible particulate matter, or discoloration is not expected and warrants discarding the vial.

Signs of degradation: Heavy cloudiness beyond the expected clear appearance, visible chunks or particulates floating in the solution, yellowing or unusual coloration, or any unusual odor. Degraded peptide should not be used.

Quality Considerations

Melanotan II quality is a particularly significant issue because this compound circulates more heavily in unregulated gray markets than almost any other research peptide. The tanning and sexual function applications have driven widespread gray-market distribution - primarily through nasal spray products sold online with no documentation of what they actually contain, at what concentration, or under what manufacturing conditions. Synthesis and purification of a cyclic heptapeptide with multiple structural modifications involves genuine technical complexity; cutting corners in synthesis produces impurities that go undetected without third-party purity testing, and the buyer has no way to evaluate this from the product appearance alone. U.S.-manufactured research peptides come with documented synthesis processes, third-party certificates of analysis, and verifiable purity data - none of which exist for gray-market nasal spray products or overseas-sourced powders with no testing documentation. For a compound where the dose-response relationship is steep and the side effect profile includes cardiovascular effects and melanocyte stimulation, the sourcing decision carries real weight.

Melanotan II Side Effects & Safety

Side Effect Spectrum

Contraindications

• History of melanoma or dysplastic nevi: A significant contraindication based on mechanism - MC1R activation stimulates melanocyte activity and proliferation throughout the body, including in existing nevi. Any compound that drives melanocyte stimulation warrants extreme caution in individuals with a history of melanoma or high-risk nevi. This is based on mechanistic reasoning rather than direct clinical evidence of MT2-induced melanoma, but the mechanistic basis is substantial enough to treat as a hard contraindication.
• Cardiovascular disease or hypertension: Sympathetic nervous system activation is a documented mechanism-based effect of MC3R and MC4R activation. Transient blood pressure changes have been noted in the clinical development of bremelanotide, the related successor compound. Individuals with cardiovascular disease, uncontrolled hypertension, or significant cardiac history should not use this compound without direct medical supervision.
• Active hormonal or endocrine conditions: Given the broad downstream effects of simultaneous activation of MC1R, MC3R, MC4R, and MC5R across multiple organ systems and the CNS, individuals with active endocrine conditions involving the hypothalamic-pituitary axis should exercise caution. Insufficient data exists to confirm safety in several endocrine contexts.

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: No safety data exists; use is not recommended without direct medical supervision, and given the compound's CNS-active and multi-receptor profile, use during pregnancy is not advisable
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• Personal or family history of melanoma or skin cancer: Given the melanocyte-stimulating mechanism, individuals with a strong personal or family history of melanoma or skin cancer represent a population where caution is clearly warranted - independent of whether formal contraindication data exists
• Individuals with significant psychiatric history: MC4R activation in limbic and hypothalamic regions may have unpredictable effects in individuals with existing mood or psychiatric conditions; insufficient data exists to characterize this risk

Red Flags - Stop Use and Seek Medical Attention If:

• Severe or persistent nausea and vomiting that does not resolve within a few hours of administration
• Significant or sustained increase in blood pressure or heart rate
• Any new or rapidly changing skin lesions, particularly changes in existing moles (nevi) in terms of size, color, border, or elevation
• Chest pain, tightness, shortness of breath, or palpitations
• Priapism - a prolonged, painful erection that does not resolve; the central pro-erectile mechanism of MT2 makes this a relevant, if uncommon, concern

Drug and Compound Interactions

No formal drug interaction studies have been published for Melanotan II specifically. Mechanism-based interaction considerations include potential additive effects with PDE5 inhibitors (sildenafil, tadalafil, vardenafil) given complementary pro-erectile mechanisms operating through different pathways - this combination has not been formally studied, and the combination of central and peripheral pro-erectile mechanisms warrants caution regarding sustained erection risk. The sympathomimetic component of MC3R and MC4R activation could theoretically interact with cardiovascular medications, antihypertensives, or stimulant compounds. Concurrent use with compounds affecting the melanocortin system or alpha-MSH pathways should be approached with caution given additive receptor activation potential.

Melanotan II Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability Melanotan II has been studied primarily via subcutaneous injection in human clinical research. The cyclic lactam structure and D-amino acid substitution provide strong resistance to peptidase degradation both at the injection site and in systemic circulation, enabling meaningful bioavailability via the subcutaneous route. Specific bioavailability percentage data comparing routes is not well-characterized in available published literature for MT2 specifically.

Distribution Melanotan II crosses the blood-brain barrier - a property directly tied to its cyclic structure. This CNS access is the mechanistic basis for its central effects on sexual function, appetite regulation, and the neuroprotective findings in animal models. Linear analogs of alpha-MSH do not readily cross the BBB, which is a key structural distinction between MT2 and its predecessors.

Half-Life Approximately 33 hours, as reported in human research protocols. This extended half-life - compared to the minutes-long half-life of native alpha-MSH - results from the combined effects of cyclization, D-phenylalanine substitution, and norleucine substitution, all of which confer resistance to the enzymatic degradation that rapidly clears the natural hormone.

Metabolism & Elimination Melanotan II is metabolized through peptide hydrolysis. One documented metabolite is bremelanotide (PT-141), formed by hydrolysis of the C-terminal amide - this metabolite became the basis for the FDA-approved compound Vyleesi for hypoactive sexual desire disorder. Complete elimination pathways and the relative contribution of renal versus hepatic clearance are not fully characterized in available published literature.

Mechanistic Research

MC1R-Mediated Melanogenesis Signaling (Evidence: Human and in vitro - Dorr et al., 1996, Journal of Investigative Dermatology)

The melanogenesis cascade triggered by MC1R activation follows a well-characterized intracellular pathway. MT2 binding elevates intracellular cyclic AMP, which activates Protein Kinase A, which phosphorylates CREB, which upregulates MITF - the master transcription factor governing melanocyte biology - which drives expression of tyrosinase, the rate-limiting enzyme in eumelanin synthesis. Dorr et al. (1996) documented visible skin pigmentation in human research subjects, providing direct evidence that this cascade operates in vivo in humans at studied doses.

Central Pro-Erectile Mechanism via MC4R (Evidence: Human clinical trial - Wessells et al., 1998, Journal of Urology)

MC4R activation in the paraventricular nucleus of the hypothalamus and spinal cord initiates pro-erectile signaling through neuronal nitric oxide release in erectile tissue. This is mechanistically distinct from PDE5 inhibitors, which act peripherally to prevent the breakdown of nitric oxide once vascular signaling is already occurring. In the Wessells et al. (1998) double-blind, placebo-controlled crossover trial - 20 men with psychogenic erectile dysfunction, 0.025 mg/kg subcutaneous dose - erection initiation occurred in 85% of active treatment administrations, with erections appearing 15-270 minutes post-injection in the complete absence of sexual stimulation.

Rabbit Cavernosal Pressure Confirmation (Evidence: Animal model - Martin et al., 2003, British Journal of Pharmacology)

Martin et al. (2003) confirmed the central melanocortin mechanism in a rabbit model measuring cavernosal pressure directly. The study demonstrated that MT-II increases cavernosal pressure through activation of central melanocortin receptors, and specifically identified the mechanism as neuronal nitric oxide release - not direct vascular action - establishing the neural basis of the pro-erectile effect at a tissue level.

Hypothalamic MC3R/MC4R - Metabolic and Appetite Mechanisms (Evidence: Animal model - Dhurandhar et al., 2013, Applied Physiology, Nutrition, and Metabolism)

Dhurandhar et al. (2013) administered Melanotan II chronically to diet-induced obese rats and documented rapid food intake suppression within hours, followed by sustained body mass reduction and decreased intra-abdominal adiposity. Body mass reduction was maintained even after feeding behavior normalized - demonstrating that thermogenic mechanisms (sympathetic nervous system activation, UCP-1 upregulation in brown adipose tissue) operate through a mechanism more resistant to tachyphylaxis than the appetite-suppression pathway. Tolerance to appetite effects developed within approximately 8-12 days of continuous administration.

MC4R-Mediated Female Sexual Behavior (Evidence: Animal model - Pfaus et al., 2004, PNAS)

Pfaus et al. (2004) documented that melanocortin receptor agonism specifically facilitated sexual solicitation behavior in female rats. This finding established that the central MC4R pathway governing sexual arousal is not limited to male physiology, providing mechanistic rationale for the successor compound bremelanotide's clinical development and FDA approval specifically for hypoactive sexual desire disorder in premenopausal women.

Condition-Focused Research

Erectile Dysfunction and Sexual Dysfunction {#research-sexual}

The Wessells et al. (1998) double-blind placebo-controlled crossover trial in men with psychogenic erectile dysfunction remains the primary human evidence anchor for Melanotan II. At 0.025 mg/kg subcutaneous, 17 of 20 men (85%) initiated erections, with a duration of penile rigidity above 80% of 41-45 minutes in the active condition versus 2-3 minutes in placebo. The follow-up Wessells et al. (2000) trial extended findings to men with both organic and psychogenic erectile dysfunction and documented increased sexual desire in 68% of active treatment administrations versus 19% in placebo. These trials established a proof of concept that was ultimately validated commercially through bremelanotide (Vyleesi), the FDA-approved successor compound. (Evidence: Strong - human clinical trial)

Pigmentation and Photoprotection {#research-pigmentation}

Dorr et al. (1996) documented visible skin pigmentation in human research subjects during early University of Arizona trials, confirming that the MC1R melanogenesis cascade operates in vivo in humans at studied doses. The broader photoprotection hypothesis - that stimulated eumelanin provides UV protection - was ultimately validated through afamelanotide (Melanotan I, Scenesse), which received FDA approval in 2019 for erythropoietic protoporphyria. Melanotan II itself has never been developed for or approved for any photoprotection indication. (Evidence: Human - pigmentation documented; clinical photoprotection indication not approved)

Metabolic and Obesity Research {#research-metabolic}

Dhurandhar et al. (2013) represents the primary published metabolic research for Melanotan II - a chronic administration study in diet-induced obese rats demonstrating sustained body mass reduction and decreased visceral adiposity. The finding that metabolic effects persist beyond appetite tolerance development is mechanistically significant, suggesting thermogenic mechanisms as a separate therapeutic target. No human clinical trial has evaluated MT2 for any metabolic or obesity indication, which represents a substantial gap in the evidence base. (Evidence: Animal model - no human data)

Neuroprotection {#research-neuro}

Separate animal studies have documented enhanced peripheral nerve regeneration in rat sciatic nerve crush models and partial protection against cisplatin-induced toxic neuropathy. These findings are consistent with the established mechanisms of MC1R-mediated neuroinflammation suppression and broader melanocortin effects on glial cell activity. All neuroprotective findings are from animal models - no human neuroprotection or cognitive data for Melanotan II exists. (Evidence: Preliminary - animal models only)

Safety & Tolerability Research

The safety and tolerability profile of Melanotan II in human subjects was characterized in the Wessells et al. (1998, 2000) clinical trials and related early University of Arizona research. The most consistently reported adverse events across human studies were nausea, facial flushing, fatigue, and spontaneous erections in male subjects. These effects were documented at the 0.025 mg/kg research dose and were described as generally transient but frequent enough - along with nevi darkening and cardiovascular concerns - to be a primary driver of Palatin Technologies' decision to abandon MT2 clinical development in 2000 in favor of the more selective metabolite bremelanotide. Long-term safety data in humans is not available in published literature, as no clinical program reached the duration required to generate it.

Research Limitations

Melanotan II has a genuinely unusual evidence profile: more published human clinical data than most unapproved research peptides, but a human evidence base limited to a small number of trials conducted in the 1990s and early 2000s before clinical development was abandoned. The Wessells et al. trials involved small populations (20 subjects in the primary ED trial), were conducted over short durations, and focused primarily on erectile function and pigmentation. No randomized controlled trials have been conducted for metabolic, weight management, neuroprotective, anti-inflammatory, or female sexual function applications - these rely entirely on animal and in vitro data. Long-term human safety data is absent. The dose used in clinical trials (0.025 mg/kg) does not reflect the range of doses documented in real-world use, and no dose-ranging or dose-safety studies have been published for most applications for which the compound is actually used. The abandonment of clinical development means the evidence base has been essentially static for over 20 years, with no new human trial data generated despite continued widespread gray-market use.

Is Melanotan II Legal? Regulatory & Sports Status

FDA status: Melanotan II is not approved by the FDA for any indication - not as a drug, dietary supplement, or cosmetic ingredient. The FDA has issued warnings regarding gray-market Melanotan II products. This should be clearly distinguished from two related compounds that did receive FDA approval: bremelanotide (Vyleesi), approved in 2019 for hypoactive sexual desire disorder in premenopausal women, and afamelanotide (Scenesse), approved in 2019 for erythropoietic protoporphyria. Melanotan II itself has no approval pathway and no active clinical development program as of July 2026.

Research Use Only (RUO): In most jurisdictions, Melanotan II occupies a gray area - not explicitly scheduled as a controlled substance in many countries, but also not approved for human use. It may be legally available for purchase as a research chemical for non-human research purposes in some jurisdictions. This classification does not confer any legitimacy for human use and should not be interpreted as a safety or efficacy endorsement.

WADA / USADA status: Melanotan II activates MC3R and MC4R, which modulate energy metabolism and sympathetic nervous system activity through pathways that overlap with performance-relevant mechanisms. The compound is not explicitly named on the current WADA prohibited list in a standalone entry, but it may fall under broader prohibited substance categories. Athletes subject to WADA-governed anti-doping rules should consult the current WADA Prohibited List directly and seek guidance from their sport's governing body before any use - the regulatory landscape for melanocortin agonists and research peptides is evolving.

Country-specific notes: The MHRA (UK) has issued specific warnings against Melanotan II use and it is unlicensed in the United Kingdom. Australia and New Zealand have issued regulatory warnings against its use. Multiple EU member states have it controlled or prohibited. Health Canada has issued warnings regarding its use. The regulatory position is consistently one of non-approval and caution across all major jurisdictions.

Detection: Testing methodologies for Melanotan II in anti-doping contexts are not well-documented in publicly available literature. Its extended half-life of approximately 33 hours means the compound and its metabolites would remain detectable for a meaningful window following administration, though specific detection window data for sports drug testing purposes is not established in available published sources.

Melanotan II vs. Alternatives

Commonly Paired With - Synergistic Stacks

• Melanotan II + PT-141 (Bremelanotide): Pairing MT2 with its own metabolite is not a rational combination - bremelanotide was developed as the successor to MT2 for overlapping indications, and they target the same MC4R pathway. This combination would represent redundant receptor activation without additive benefit and with potential for additive side effects; it is not a documented or recommended practice.
• Melanotan II + PDE5 inhibitors (sildenafil, tadalafil): A community-documented pairing based on complementary mechanisms - MT2 works centrally to initiate arousal signaling while PDE5 inhibitors work peripherally to maintain the vascular response. This combination has not been formally studied, and the combination of central and peripheral pro-erectile mechanisms creates an interaction scenario that warrants caution, particularly regarding sustained erection risk (priapism).

Alternatives - When Another Peptide May Be Considered

PT-141 (Bremelanotide / Vyleesi) PT-141 is the most direct successor to Melanotan II for sexual function applications - a metabolite of MT2 that was developed as a standalone compound, received FDA approval in 2019 as Vyleesi for HSDD in premenopausal women, and works through the same central MC4R mechanism. It lacks MT2's pigmentation activity and metabolic effects, but its more selective profile and regulatory approval make it the preferable option for sexual function applications where the tanning and metabolic side effects of MT2 are not desired.

Afamelanotide (Melanotan I / Scenesse) Afamelanotide is the linear alpha-MSH analog developed for photoprotection applications - receiving FDA approval in 2019 for erythropoietic protoporphyria. It primarily activates MC1R without the CNS penetration of MT2, producing pigmentation effects without the central sexual function, appetite, or neurological effects. For users whose primary interest is the tanning or photoprotective effect, afamelanotide represents the clinically developed and approved path - though it is approved only for a specific medical indication.

Kisspeptin-10 Kisspeptin-10 is a neuropeptide that stimulates gonadotropin-releasing hormone (GnRH) release and has documented effects on sexual arousal and attraction in human studies, through a mechanistically distinct pathway from melanocortin agonism. It represents an alternative approach to central sexual function modulation for individuals interested in arousal effects without the pigmentation and metabolic effects of MT2.

Comparison table:

Build Your Protocol

FAQs

What is Melanotan II?

Melanotan II (MT-II) is a synthetic cyclic heptapeptide developed at the University of Arizona as an analog of alpha-melanocyte-stimulating hormone. It is approximately 1,000 times more potent than the natural hormone and activates four melanocortin receptor subtypes - MC1R, MC3R, MC4R, and MC5R - producing effects on skin pigmentation, sexual function, appetite, and energy metabolism simultaneously.

What does Melanotan II do?

The Melanotan II peptide stimulates skin darkening without UV exposure, initiates erections through central nervous system pathways, increases sexual desire in males and females, suppresses appetite through hypothalamic receptors, and increases thermogenesis and fat mobilization. These effects occur simultaneously because MT2 activates multiple melanocortin receptors across different organ systems at once.

How long does Melanotan II take to work?

For sexual function, published clinical trial data shows onset between 15 and 270 minutes following subcutaneous injection. For pigmentation, visible skin darkening typically appears within 2-5 days of initial administration, building cumulatively over weeks and persisting for months after cessation. Appetite-suppressing effects appear rapidly in animal models but develop tolerance within approximately 8-12 days of continuous use.

What is the typical dose of Melanotan II?

The dose used in primary published human clinical trials is 0.025 mg/kg administered via subcutaneous injection - the most evidence-based reference point available. Real-world protocol doses vary from this research reference. Melanotan II is not approved for human use in any jurisdiction, and no clinically established optimal dose exists outside the controlled trial context.

Is Melanotan II legal?

Melanotan II is not approved for human use by the FDA, MHRA (UK), Health Canada, or regulatory agencies in Australia, the EU, or any other major jurisdiction. In many countries it exists in a regulatory gray area - not explicitly scheduled as a controlled substance but not legal for human use. It should not be confused with bremelanotide (Vyleesi) or afamelanotide (Scenesse), which are related but distinct FDA-approved compounds.

Can Melanotan II be taken orally?

No. Oral administration is not a viable route for systemic effects. As a peptide, it is broken down by gastric acid and digestive enzymes before reaching systemic circulation in meaningful concentrations. While its cyclic structure provides greater enzymatic resistance than native alpha-MSH, this protection is insufficient to survive the full gastrointestinal environment. All published research used subcutaneous injection.

Does Melanotan II permanently change moles or skin lesions?

Melanotan II activates MC1R, which stimulates melanocyte activity throughout the body including in existing moles (nevi). Darkening of existing nevi is a documented side effect in human studies and is mechanistically expected. Whether any darkening is permanent depends on duration of use and individual biology. Any new mole formation, rapid changes in existing moles, or development of irregular skin lesions warrants immediate evaluation by a dermatologist regardless of cause.

How does Melanotan II differ from a real tan?

A natural tan occurs because UV radiation damages DNA in skin cells, triggering a protective melanin response. Melanotan II bypasses this damage signal entirely - it directly activates the MC1R receptor that drives melanin production, generating eumelanin without UV exposure. The resulting pigmentation looks similar to a UV tan but is produced through a different upstream trigger that does not involve UV-associated DNA damage. This does not eliminate risk - the melanocyte stimulation itself carries theoretical concerns for individuals with a history of melanoma or dysplastic nevi.

Why was Melanotan II abandoned for clinical development?

Palatin Technologies abandoned clinical development in 2000 primarily because MT2's non-selective receptor activation produced unavoidable off-target effects. Any therapeutic use simultaneously activated all four receptor subtypes, producing nausea, cardiovascular effects, spontaneous erections, and melanocyte stimulation as a package. The solution was to develop more selective successor compounds: bremelanotide (targeting MC3R/MC4R for sexual dysfunction) and afamelanotide (targeting primarily MC1R for photoprotection), both of which received FDA approval in 2019.

Final Thoughts

Melanotan II occupies a genuinely unusual position in the peptide research landscape. It has more published human clinical data than most unapproved research compounds - a series of double-blind trials from the University of Arizona in the 1990s that produced real, quantified outcomes in men with erectile dysfunction. That evidence is real and not trivial. At the same time, clinical development was abandoned precisely because the compound's non-selective receptor profile meant that targeting any one of its effects inevitably produced the full range of effects across all four activated receptor subtypes. The research eventually led directly to two FDA-approved compounds - bremelanotide and afamelanotide - which represent the refined, selective successors to what Melanotan II started.

The practical reality is that Melanotan II remains unapproved in every jurisdiction, with a side effect profile that was specifically deemed unacceptable for regulatory development. The nevi darkening concern is not theoretical - MC1R activation of melanocytes is the core mechanism of action, and anyone with a personal or family history of melanoma or dysplastic nevi should treat this as a hard contraindication. The cardiovascular component is mechanism-based, not incidental. Gray-market nasal spray products add compounding risk through unknown purity, unverified dosing, and no quality documentation. These are not reasons to dismiss the science - the science is genuinely interesting - but they are reasons to treat this compound with considerably more caution than its tanning and sexual function marketing framing typically suggests.

For those interested in the specific applications Melanotan II has been studied for, the clearer paths forward are through its successors. PT-141 (bremelanotide / Vyleesi) addresses the sexual function applications with a better-characterized safety profile and FDA approval. Afamelanotide addresses the photoprotection applications for the specific medical population for which it was developed. MyPeptidePal can help you understand where the Melanotan II peptide fits relative to these options based on your specific goals and health history - building a personalized picture of what the evidence actually supports for your situation.

References

1. Wessells, H., Fuciarelli, K., Hansen, J., Hadley, M. E., Hruby, V. J., Dorr, R., & Levine, N. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology, 160(2), 389-393.

2. Wessells, H., Gralnek, D., Dorr, R., Hruby, V. J., Hadley, M. E., & Levine, N. (2000). Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology, 56(4), 641-646.

3. Dorr, R. T., Lines, R., Levine, N., Brooks, C., Xiang, L., Hruby, V. J., & Hadley, M. E. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Journal of Investigative Dermatology, 107(2), 296-297.

4. Martin, W. J., McGowan, E., Cashen, D. E., Gantner, M. E., Rosenthal, D. I., & Legos, J. J. (2003). Activation of melanocortin MC4 receptors increases erectile activity in rats. British Journal of Pharmacology, 139(4), 755-764.

5. Pfaus, J. G., Shadiack, A., Van Soest, T., Tse, M., & Molinoff, P. (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences, 101(27), 10201-10204.

6. Dhurandhar, E. J., Allison, D. B., van Groen, T., & Kadish, I. (2013). Hunger in the absence of caloric deprivation: a role for melanocortin signaling in weight regulation. Applied Physiology, Nutrition, and Metabolism, 38(8), 905-909.